Orchid Chemicals & Pharmaceuticals Ltd has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Cefpodoxime Proxetil Tablets.

The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Cefpodoxime Proxetil Tablets. The product is available in two dosage strengths, 100 mg and 200 mg.

Cefpodoxime Proxetil is a 3rd generation cephalosporin antibiotic which has a broad spectrum activity against organisms causing infectious diseases.

With limited generic competition in this product, Orchid hopes to garner a sizeable market share and revenues in the US market.